

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION FRAMEWORK AGREEMENT WITH CHINA STATE CONSTRUCTION INTERNATIONAL MEDICAL INDUSTRY DEVELOPMENT CO., LTD.

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to keep shareholders and potential investors of the Company informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on 28 December 2022, after trading hours, the Company and China State Construction International Medical Industry Development Co., Ltd. (“**CSIM**”, together with the Company, the “**Parties**”) entered into a strategic cooperation framework agreement (the “**Framework Agreement**”), pursuant to which the Parties have agreed to cooperate with respect to the development of (i) high-quality medical and biotechnology construction projects; and (ii) education, training, scientific research and other services related to medical science and biotechnology (the “**Cooperation**”).

STRATEGIC COOPERATION FRAMEWORK AGREEMENT

The principal terms of the Framework Agreement are set out below:

Date: 28 December 2022

Parties: (i) CSIM; and
(ii) the Company

To the best of the Directors' knowledge and information, having made all reasonable enquiries, CSIM and its ultimate beneficial owners are third parties independent of the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules")).

Term: Commencing from the date on which the Framework Agreement is signed

Subject Matter: The parties specifically agreed to cooperate on the following (among other matters):

- (i) the Parties will actively liaise with the Hong Kong and Mainland governments, cherry-pick high-quality medical and biotechnology construction projects, and will target the Guangdong-Hong Kong-Macao Greater Bay Area as the primary cooperation location to vigorously promote the implementation of projects in the Northern Metropolis area, Guangdong-Hong Kong-Macao Greater Bay Area and the whole of China;
- (ii) the Parties will give full play to their respective resources, actively develop medical and biotechnology construction projects demanded by local governments including but not limited to high-standard international hospitals, international health complexes, international health communities, one health and biotechnology industrial parks; and
- (iii) the Parties will actively develop education, training, scientific research and other services related to medical science and biotechnology, and will make full use of professionals with experience and expertise in different fields to provide training and consultancy services to scientific and educational institutions, government departments, business groups and others in need in the Guangdong-Hong Kong-Macao Greater Bay Area and the whole of China.

Non-legally binding effect: The Framework Agreement does not constitute a legally binding commitment or obligation on the parties in respect of the Cooperation.

REASONS AND BENEFITS OF ENTERING INTO THE FRAMEWORK AGREEMENT

CSIM is the subsidiary of China State Construction International Holdings Limited (Stock Code: 3311), one of the largest contractors in the construction market in Hong Kong and Macau. CSIM has participated in more than a quarter of Hong Kong's hospital construction projects, including the design and construction projects of Hong Kong Children's Hospital and Hong Kong Chinese University Hospital, etc., and has been responsible for the planning, design and construction of the central government's anti-epidemic projects in Hong Kong.

The Board believes that the formation of the strategic partnership with CSIM through the Framework Agreement and the Cooperation will be beneficial to the development of the Group's businesses and in turn maximise return to the Company and its shareholders in the long run.

GENERAL

The Board wishes to emphasise that while the Framework Agreement forms the basis for the long-term strategic cooperation between the Company and CSIM, the entering into of any definitive cooperation agreement(s) (if any) is subject to further negotiations between the Parties. The Board wishes to remind its shareholders that there is no assurance that any definitive cooperation agreement(s) will be signed between the Parties concerned. The Cooperation or any transactions contemplated under the definitive cooperation agreement(s), if materialise, may or may not constitute notifiable transactions for the Company under Chapter 19 of the GEM Listing Rules. Further announcement(s) will be made by the Company to comply with the applicable requirements under the GEM Listing Rules as and when necessary.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 28 December 2022

As at the date of this announcement, the board of Directors comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.